Executive SummaryDivestiture of Elizabeth Arden cosmetics subsidiary to Faberge for $700 mil. completed Dec. 22. However, Lilly said undisclosed restructuring plans may off-set, "in whole or part," gain from the Arden sale. Additionally, Lilly's board approved a plan to repurchase up to $1 bil. in common stock.
You may also be interested in...
UCB's R&D efforts include late-stage diverse but complementary immunologicals and anti-neuroinflammatories.
Janssen and AstraZeneca are among a raft of companies that might this week find out whether the European Medicines Agency will recommend approval of their products for expanded therapeutic indications.
Shares in Iovance Biotherapeutics have soared this week amid reports the US clinical-stage biotechnology company is in active M&A talks.